Patients with and without obesity experienced significant pain reductions and improved functioning following telerehabilitation for chronic musculoskeletal pain.
Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...
The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
The following is a summary of “Real-world satisfaction and experience with injection and autoinjector device for ofatumumab ...
On Amazon, a good product rating percentage is generally considered to be 80% or higher, which corresponds to a four-star ...
Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...
We view Fanuc’s capital allocation as Exemplary, as the company has been efficiently allocating capital to both its operations and shareholders. Fanuc’s balance sheet has been healthy, without any ...
Results of a study showed administration of IV tranexamic acid within 15 minutes of incision did not significantly improve ...
Long-term treatment with lebrikizumab may be beneficial for patients with atopic dermatitis that were not initially ...
Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
BIOTRONIK Neuro will unveil new data from the BENEFIT-03 clinical study at the North American Neuromodulation Society (NANS) 2025 Annual Meeting. The findings highlight the transformative potential of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback